NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Akorn, Inc. (NASDAQ: AKRX) concerning possible violations of federal securities laws.
On February 26, 2018, Fresenius SE & Co. KGaA—which had been expected to close on an acquisition of Akorn—announced that it is conducting an investigation into alleged breaches of U.S. Food and Drug Administration “data integrity requirements relating to product development at Akorn.” Following this news, shares of Akorn were down more than 33% on intraday trading on February 27, 2018. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.